SCHEMBL23604609

SCHEMBL23604609

COC(=O)c1cc(Cl)c(C)c(Cl)c1OC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.49
HPGD P15428 4/20 0.46
KDM4E B2RXH2 7/20 0.43
ALDH1A1 P00352 4/20 0.43
POLB P06746 3/20 0.43
HSD17B10 Q99714 2/20 0.43
USP2 O75604 1/20 0.43
GALK1 P51570 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
HTT P42858 1/20 0.42
ABL1 P00519 1/20 0.40
PTGS2 P35354 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
NQO2 P16083 1/20 0.38
TAS1R3 Q7RTX0 1/20 0.38
TAS1R1 Q7RTX1 1/20 0.38
TAS1R2 Q8TE23 1/20 0.38
LMNA P02545 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10714382 0.84 ALDH1A1 (0.38) GAAHPGDKDM4EALDH1A1HSD17B10
SCHEMBL8159962 0.84 GAA (0.49) GAAHPGDKDM4EHTTABL1
SCHEMBL6289137 0.83 HPGD (0.47) GAAHPGDKDM4EALDH1A1POLB
SCHEMBL10472303 0.81 GAA (0.55) GAAHPGDKDM4EALDH1A1POLB
SCHEMBL24136731 0.81 GAA (0.50) GAAHPGDKDM4EALDH1A1POLB
SCHEMBL30466420 0.81 GAA (0.50) GAAHPGDKDM4EALDH1A1POLB
SCHEMBL6782175 0.80 GAA (0.54) GAAHPGDKDM4EALDH1A1POLB
SCHEMBL23512993 0.79 GAA (0.45) GAAHPGDALDH1A1HTTABL1
SCHEMBL13561974 0.79 SMN1; SMN2 (0.49) GAAHPGDKDM4EALDH1A1GALK1
SCHEMBL23822989 0.78 GAA (0.47) GAAHPGDKDM4EALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230054028-A1 PD-L1 ANTAGONIST COMPOUND ADLAI NORTYE BIOPHARMA CO., LTD. (CN) 2023-02-23 US disclosed
EP-4083032-A1 PD-L1 ANTAGONIST COMPOUND Adlai Nortye Biopharma Co., Ltd. (CN) 2022-11-02 EP disclosed
WO-2021129584-A1 PD-L1 ANTAGONIST COMPOUND 杭州阿诺生物医药科技有限公司 2021-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230054028-A1 PD-L1 ANTAGONIST COMPOUND CD274, PDCD1LG2, PDCD1 GAA 1336/4885HPGD 1226/4885KDM4E 1659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.